Biotechnology Clinical-stage gene therapy company MeiraGTx Holdings says it has received a $30 million payment from Janssen Pharmaceuticals, part of US healthcare giant Johnson & Johnson, for a clinical milestone in the Phase III Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP). 27 January 2022